EUVIMEDEUVIMED entdecken
Multizentrische Studie

Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors ( RESO ‐ ADOC study)

Ziad Reguiai, Pierre André Becherel, Jean Luc Perrot, Claire Boulard, Anne Claire Fougerousse iD, Edouard Begon, Antoine Badaoui, Claire Poreaux, Josiane Parier, Anne-Laure Liegeon, Matthieu Levavasseur, Anne-Claire Bing und 3 weitere

Journal of the European Academy of Dermatology and Venereology · 2024

DOI: 10.1111/jdv.20233 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Ziad Reguiai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Polyclinique Courlancy, Reims-Bezannes, France. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Conjunctivitis, Janus Kinase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: ResoMed.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials and real‐life data have reported an increased incidence of conjunctivitis in patients treated with dupilumab for their atopic dermatitis (AD). Although mostly mild in severity, in some cases conjunctivitis will appear or increase after dupilumab initiation, which can lead to dupilumab discontinuation.

Objectives

(1) To describe the characteristics of patients developing conjunctivitis requiring discontinuation of dupilumab; and (2) to analyse the factors associated with a complete conjunctivitis improvement after dupilumab discontinuation and a switch to tralokinumab or Janus kinase inhibitors.

Methods

This was a multicentre retrospective cohort study that included all patients with AD treated with dupilumab who developed conjunctivitis leading to dupilumab discontinuation and switching to tralokinumab or Janus kinase inhibitors in daily practice. Data on patients, their AD and conjunctivitis were analysed at the inclusion visit (corresponding to discontinuation of dupilumab and the institution of new AD treatment), at visit 2 (3–6 months after inclusion) and at visit 3 (corresponding to the last medical visit).

Results

After multivariate analysis, the only factors associated with a complete resolution of dupilumab‐associated conjunctivitis at visit 2 and/or visit 3 were conjunctivitis duration (OR 8.98, 95% CI 1.47–55) ( p = 0.018), personal history of asthma (OR 10.66, 95% CI 1.82–62.63) ( p = 0.009) and switching from dupilumab to Janus kinase inhibitors (OR 17.11, 95% CI 2.94–99.66) ( p = 0.002).

Conclusions

Although uncommon, severe dupilumab‐associated conjunctivitis is more frequent in daily life compared to its incidence in the dupilumab pivotal trials. In these cases, our study suggests that a rapid switch to another molecule, particularly a Janus kinase inhibitor, should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedConjunctivitisJanus Kinase InhibitorsHumansRetrospective StudiesMaleFemaleAdultMiddle AgedDrug SubstitutionAntibodies, Monoclonal

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedJanus Kinase InhibitorstralokinumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Dermatology, Polyclinique Courlancy, Reims-Bezannes, France.
  • Dermatology and Clinical Immunology Unit, Antony Hospital, Antony, France.
  • CHU Saint Etienne, Saint-Etienne, France.
  • Centre Hospitalier du Havre, Le Havre, France.
  • Hôpital d'Instruction Des Armées Begin, Saint Mandé, France.
  • Centre Hospitalier René Dubos, Pontoise, France.

ORCID-Profile: Anne Claire Fougerousse

Förderung

  • ResoMed

Zitieren

APA

Reguiai, Z., Becherel, P. A., Perrot, J. L., Boulard, C., Fougerousse, A. C., Begon, E., Badaoui, A., Poreaux, C., Parier, J., Liegeon, A. L., Levavasseur, M., Bing, A. C., Estève, E., Maccari, F., & GEM reso‐Dermatologie and OMCCI Group (2024). Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors ( RESO ‐ ADOC study). Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20233

Vancouver

Reguiai Z, Becherel PA, Perrot JL, Boulard C, Fougerousse AC, Begon E, et al. Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors ( RESO ‐ ADOC study). Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.20233

BibTeX
@article{Reguiai2024,
  author = {Reguiai, Ziad and Becherel, Pierre André and Perrot, Jean Luc and Boulard, Claire and Fougerousse, Anne Claire and Begon, Edouard and Badaoui, Antoine and Poreaux, Claire and Parier, Josiane and Liegeon, Anne-Laure and Levavasseur, Matthieu and Bing, Anne-Claire and Estève, Eric and Maccari, François and GEM reso‐Dermatologie and OMCCI Group, GEM reso‐Dermatologie and OMCCI Group},
  title = {Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors ( RESO ‐ ADOC study)},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  doi = {10.1111/jdv.20233}
}
Kostenlos starten →